Skip to content

Efficacy and safety of epicutaneous immunotherapy for severe egg allergy; Long term trial

Efficacy and safety of epicutaneous immunotherapy for severe egg allergy; Long term trial - Epicutaneous immunotherapy for egg allergy

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000025381
Enrollment
20
Registered
2016-12-23
Start date
2016-12-26
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Food allergy

Interventions

Cutaneous application of ovomucoid-containing hydrogel patch 12 hours a day for 48 weeks Outaneous application of ovomucoid-containing hydrogel patch 12 hours a day for 24 weeks

Sponsors

National Hospital Organization Mie National Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Egg allergy diagnosed by oral food challenge (OFC) without tendency of natural outgrow 2) Cooked egg dose threshold of OFC =<2g and underwent cutaneous application of ovomucoid-containing hydrogel patch or hydrogel patch without containing antigen for 24 weeks. 3)Cooked egg dose threshold of OFC =<2g after intervetion of 2).

Exclusion criteria

Exclusion criteria: 1) Allergy to soy and milk 2) Large change in intake levels of egg before 3 months of the trial 3) Complication or past history of heart, liver and kidney diseases 4) Uncontrolled asthma or atopic dermatitis

Design outcomes

Primary

MeasureTime frame
Change of dose threshold in oral egg challenge from 24 weeks to 48 weeks of treatment

Secondary

MeasureTime frame
1.Change of dose threshold in oral egg challenge after 24 weeks of treatment 2.Safety:local reaction,systemic immediate-type allergic reaction and other 3.Prick test 4.Specific IgE and IgG4 5.Basophil activation test

Countries

Japan

Contacts

Public ContactYu Kuwabara

National Hospital Organization Mie National Hospital Allergy center

yu_surrealist@hotmail.co.jp+81592322531

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026